TN-19 Antithymocyte Globulin (ATG) and pegylated granulocyte colony stimulating factor (GCSF) in New Onset Type 1 Diabetes
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to learn if either one of these treatments could also help people with newly diagnosed type 1 diabetes by delaying or stopping further destruction of beta cells.
Description
The purpose of this study is to determine the safety and ability of lose dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Details
| Condition | type 1 diabetes |
|---|---|
| Age | 12years - 46years |
| Clinical Study Identifier | TX4447 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.